Astrana Health reports Q3 EPS 1c vs. 33c last year

Reports Q3 revenue $956.0M, consensus $952.83M. Reports Q3 adjusted EBITDA $68.5M, up 52% from $45.2M. “Astrana delivered solid third quarter results and demonstrated strong momentum in our first quarter of combined operations with Prospect Health,” said CEO Brandon Sim. “Prospect’s performance exceeded our expectations, and integration is progressing well, expanding our scale, capabilities, and physician reach across key markets. While our full-year outlook reflects the updated timing of certain full-risk contract transitions, which we expect to complete in the first quarter of 2026, underlying clinical and cost trend performance across both the legacy Astrana and Prospect businesses remain strong. We continue to execute with discipline and focus on building a more coordinated, high-quality, and accessible care delivery platform for the long term.”